Brief: WuXi Biologics Posts FY Revenue Of RMB18,675.4 Mln
25/03/2025 08:45
March 25 (Reuters) - WuXi Biologics (Cayman) Inc 2269.HK: FY REVENUE RMB 18,675.4 MILLION FY GROSS MARGIN 41% FY NET INCOME RMB 3,945.4 MILLION FY GROSS PROFIT RMB 7,650.8 MILLION Further company coverage: 2269.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on WuXi Biologics (Cayman)
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
CanSino leads HK-listed vaccine makers lower as BioNTech halts mRNA trial
WuXi Biologics H1 net profit up on margin expansion
Brief: WuXi Biologics Logs HY Net Profit Attributable RMB 2,439.8 Mln